Quick Takeaways
- BlackRock, Inc. filed SCHEDULE 13G/A for Allogene Therapeutics, Inc Common Stock (ALLO).
- Disclosed ownership: 5.3%.
- Date of event: 31 Mar 2025.
BlackRock, Inc. - 31 Mar 2025 SCHEDULE 13G/A Report for Allogene Therapeutics, Inc Common Stock (ALLO)
- Filing Manager
- BlackRock, Inc.
- Reporting Manager
- BlackRock, Inc.
- Symbol
- ALLO
- Shares outstanding
- 216,039,226 shares
- Disclosed Ownership
- 11,450,079 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G/A
- Filing time
- 17 Apr 2025, 09:35:33 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"BlackRock, Inc. disclosed 5.3% ownership in Allogene Therapeutics, Inc Common Stock (ALLO) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Apr 2025, 09:35.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| BlackRock, Inc. | 5.3% | 11,450,079 | 11,294,846 | 0 | Spencer Fleming | Managing Director |